AbbVie
Develops immunology, neuroscience, oncology, and aesthetics products led by Skyrizi and Rinvoq.
$255.80
After-hours close+0.33 (+0.13%)
At close$255.47(−1.04%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Oct 2026 | $3.86 | — | — |
| Jul 2026 | $3.61 | $3.65 | +1.1% |
| Apr 2026 | $2.59 | $2.65 | +2.3% |
| Feb 2026 | $2.65 | $2.71 | +2.3% |
| Oct 2025 | $1.77 | $1.86 | +5.1% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Jul 2025 | |||
| Apr 2025 | |||
| Jan 2025 | |||
| Oct 2024 | |||
| Jul 2024 | |||
| Apr 2024 | |||
| Feb 2024 | |||
| Oct 2023 | |||
| Jul 2023 | |||
| Apr 2023 | |||
| Feb 2023 | |||
| Oct 2022 | |||
| Jul 2022 | |||
| Apr 2022 | |||
| Feb 2022 | |||
| Oct 2021 | |||
| Jul 2021 | |||
| Apr 2021 | |||
| Feb 2021 | |||
| Oct 2020 | |||
| Jul 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Jul 2019 | |||
| Apr 2019 | |||
| Jan 2019 | |||
| Nov 2018 | |||
| Jul 2018 | |||
| Apr 2018 | |||
| Jan 2018 | |||
| Oct 2017 | |||
| Jul 2017 | |||
| Apr 2017 | |||
| Jan 2017 | |||
| Oct 2016 | |||
| Jul 2016 | |||
| Apr 2016 | |||
| Jan 2016 | |||
| Oct 2015 | |||
| Jul 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Oct 30, 2026 | $3.86 | — | — | $17.31B | — | — |
| Jul 31, 2026 | $3.61 | $3.65 | +1.1% | $16.80B | $16.99B | +1.1% |
| Apr 29, 2026 | $2.59 | $2.65 | +2.3% | $14.72B | $15.00B | +1.9% |
| Feb 4, 2026 | $2.65 | $2.71 | +2.3% | $16.41B | $16.62B | +1.2% |
| Oct 31, 2025 | $1.77 | $1.86 | +5.1% | $15.59B | $15.78B | +1.2% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | ||||||
| Jul 31, 2025 | ||||||
| Apr 25, 2025 | ||||||
| Jan 31, 2025 | ||||||
| Oct 30, 2024 | ||||||
| Jul 25, 2024 | ||||||
| Apr 26, 2024 | ||||||
| Feb 2, 2024 | ||||||
| Oct 27, 2023 | ||||||
| Jul 27, 2023 | ||||||
| Apr 27, 2023 | ||||||
| Feb 9, 2023 | ||||||
| Oct 28, 2022 | ||||||
| Jul 29, 2022 | ||||||
| Apr 29, 2022 | ||||||
| Feb 2, 2022 | ||||||
| Oct 29, 2021 | ||||||
| Jul 30, 2021 | ||||||
| Apr 30, 2021 | ||||||
| Feb 3, 2021 | ||||||
| Oct 30, 2020 | ||||||
| Jul 31, 2020 | ||||||
| May 1, 2020 | ||||||
| Feb 7, 2020 | ||||||
| Nov 1, 2019 | ||||||
| Jul 26, 2019 | ||||||
| Apr 25, 2019 | ||||||
| Jan 25, 2019 | ||||||
| Nov 2, 2018 | ||||||
| Jul 27, 2018 | ||||||
| Apr 26, 2018 | ||||||
| Jan 26, 2018 | ||||||
| Oct 27, 2017 | ||||||
| Jul 28, 2017 | ||||||
| Apr 27, 2017 | ||||||
| Jan 27, 2017 | ||||||
| Oct 28, 2016 | ||||||
| Jul 29, 2016 | ||||||
| Apr 28, 2016 | ||||||
| Jan 29, 2016 | ||||||
| Oct 30, 2015 | ||||||
| Jul 24, 2015 | ||||||